Study Phase 2

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE) Induction Therapy in Patients With Plaque-type Psoriasis

Trial Information

Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaImmune System DiseasesEnrollment249% Female30%% WhiteN/A
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberCR003124 / C0168T31Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)45

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.